Leukocytoclastic vasculitis (LCV) or hypersensitivity vasculitis refers to small blood vessel inflammation. It’s also known as hypersensitivity angiitis, cutaneous small-vessel vasculitis, cutaneous LCV or cutaneous leukocytoclastic angiitis. LCV commonly presents with palpable purpura on the lower extremities. It can be seen secondary to underlying systemic autoimmune diseases, chronic infections, and malignancies. Staphylococcus aureus, Mycobacterium, Neisseria, Chlamydia, and HIV triggers the LCV.
Treatment of leukocytoclastic vasculitis varies depending on the symptoms and cause. Eliminating irritating agent such as drugs and treating the underlying infection will remove the symptoms of leukocytoclastic vasculitis disease. Most of the idiopathic leukocytoclastic vasculitis are mild and can be treated with supportive treatments such as leg elevation, compression stockings, rest, and antihistamines. In severe, chronic or resistant cases, a tapering dose of corticosteroids for a 4-6 week is used. The medications like prednisone, pentoxifylline, cyclophosphamide, and azathioprine have proven to be effective in the treatment of the Leukocytoclastic vasculitis. Another treatment is symptomatic and supportive.
To remain ‘ahead’ of your competitors, request for a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=5669
What are the Key Trends Impacting Growth of the Global Leukocytoclastic Vasculitis Market?
Increasing incidences of blood vessel inflammatory diseases is a key factor responsible for the growth of the Global leukocytoclastic vasculitis market. Rising prevalence of metabolic, chronic and circulatory diseases like peripheral arterial disease (PAD) has also increased demand for minimally invasive procedures for the treatment of leukocytoclastic vasculitis. However Increase in healthcare infrastructures led to enhance funding by the leading players on the development of new alternative drugs, on investment in research and development programs for introduction of advance technologies such as the use of MRIMRA devices i.e. Magnetic Resonance Imaging Magnetic Resonance Angiography devices. Increases in the use of MRIMRA for diagnosis and treatment are expected to provide better results to the manufactures and allow them to work more efficiently, thereby driving the Global leukocytoclastic vasculitis market growth.
How Global Leukocytoclastic Vasculitis Market is Reshaping by Increasing Demand for Biosimilars?
Biosimilars are leading the drug type segment due to better clinical outcomes in patients suffering from leukocytoclastic vasculitis and promising biosimilar drugs in the pipeline with enhanced drug safety and efficacy. Development and USFDA approval of newer biosimilars such as rituximab for the treatment of leukocytoclastic vasculitis diseases in combination with other drugs like prednisolone are widely used to treats severe cases. Leukocytoclastic vasculitis therapy is expected to rise effectively as therapy for leukocytoclastic vasculitis depends on the type of vasculitis, the severity of the condition and organs which are affected. Leukocytoclastic vasculitis treatment is aimed to reduce inflammation in the affected blood vessels. People suffering from severe vasculitis are treated with prescription medicines. People with mild leukocytoclastic vasculitis are treated with over-the-counter pain or anti-inflammatory drugs, such as ibuprofen acetaminophen, aspirin, or naproxen is anticipated to further expand the segmental market.
Speak To Research Analyst For Detailed Insights: https://www.factmr.com/connectus/sample?flag=AE&rep_id=5669
What are the Key Challenges that may Restrain Growth of the Global Leukocytoclastic Vasculitis Market?
Lack of awareness among the elder population about Leukocytoclastic vasculitis and associated treatment is the major factor hampering Global leukocytoclastic vasculitis market growth. The high cost associated with biosimilars for the treatment of leukocytoclastic vasculitis and stringent regulatory approval process acts as a major restraint for the growth of the Global leukocytoclastic vasculitis market over the coming years.
Key Segments of Global leukocytoclastic vasculitis market Covered in the Report
Based on Drug type, the Global leukocytoclastic vasculitis market has been segmented as
- Biosimilars
- Rituximab
- Infliximab
- Adalimumab
- Corticosteroids
- Immunosuppressive Agent
- NSAIDs
- Colchicine
- Sulfones
Based on the indication, the Global leukocytoclastic vasculitis market has been segmented as
- Infections
- Malignancy
- Connective Tissue Disease
- Autoimmune Disease
Based on the region, the Global leukocytoclastic vasculitis market has been segmented as
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=5669
Competitive Landscape
Key players such as
- Hoffman La Roche Ltd.
- GlaxoSmithKline Plc
- Baxter International
- Eli Lilly & Company
- AstraZeneca
- Teva Pharmaceuticals
- Novo Nordisk A/S
- Daiichi Sankyo
- Bristol Myers Squibb Company
- ChemoCentryx
- Celgene Corporation
- Merck & Co
- Goodwin Procter LLP
- And others are actively involved in offering vegan protein for different applications.
What strategies are the Key Players adopting for Increasing their Market Share in the Global leukocytoclastic vasculitis market?
Key players are adopting key strategies such as Mergers and acquisitions, product launches, strategic partnerships and geographical expansions in the Global leukocytoclastic vasculitis market. For instance, in 2020, Amgen’s RIABNI (rituximab-arrx) got U.S. Food and Drug Administration (FDA) approval as a biosimilar to Rituxan (rituximab), for the treatment of adult patients with Granulomatosis Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) and In September 2019 Roche’s Rituxan (rituximab), got U.S. Food and Drug Administration approval for the treatment of granulomatosis with microscopic polyangiitis (MPA) and polyangiitis (GPA) in paediatric patients with age more than 2 years. Granulomatosis with polyangiitis and microscopic polyangiitis are rare and possibly life-threatening diseases that mainly affects small and medium-sized blood vessels. Similarly, Bristol Myers Squibb Company got the U.S. Food and Drug Administration (FDA) has approval for Rituxan (rituximab) to update the label to include information on follow up treatment of adult patients with GPA and MPA.
Some of the leading manufactures are investing in research and development to launch a new product and to gain competitive advantage. For instance, in 2020, Teva pharmaceuticals Inc. signed an exclusive partnership agreement with Celltrion Healthcare to launched TRUXIMA (rituximab-abbs) Injection, in the United States for GPA and MPA in adult patients in combination with glucocorticoids. Celltrion entered into a collaboration agreement with Intract Pharma to develop the World’s first oral infliximab and they launched REMSIMA SC (infliximab) in Europe for GPA and MPA in adult patients.
Key players are investing in research and development activities to develop new therapeutic options with more clinical outcomes and launching biosimilar of the existing drugs for the treatment of leukocytoclastic vasculitis in lower to middle-income countries.
What are the Key Opportunities for key players in the Global leukocytoclastic vasculitis market?
The rise of alternative biosimilars in the Global leukocytoclastic vasculitis market has garnered significant attention, with large-scale pharmaceutical retailers promoting biosimilars to mainstream consumers. Concurrently, investments for increasing the production of drugs used in leukocytoclastic vasculitis treatment are showing increasing growth. The growing population and increase in healthcare expenditure in developed and developing countries are driving the demand for leukocytoclastic vasculitis treatment. However, consumers being more concerned about health and sustainability issues, are contributing to the growth of the Global leukocytoclastic vasculitis market.
The high cost of biosimilars for the treatment of leukocytoclastic vasculitis encourages the pharmaceutical companies to invest in research and development to find alternative biosimilars, which are more cost-effective with positive outcomes. Hence, growth opportunities abound for companies that will offer innovative, high-quality, and cost-effective drugs for the treatment of leukocytoclastic vasculitis in the market.
Why North America Is A Big Market For Leukocytoclastic Vasculitis?
North America will be the largest market on account of increasing incidences of leukocytoclastic vasculitis, giant cell arteritis and Takayasu arteritis. The key factors responsible for North America market growth are rising prevalence of leukocytoclastic vasculitis and presence of key market players such as Celgene Corporation, Bristol Myers Squibb Co. etc. which actively engaged in the drug discovery for vasculitis treatment. Rising prevalence of chronic diseases due to sedentary lifestyles, increase in ageing population who are more prone to cardiovascular diseases, high demand for minimally invasive procedures, and the existence of technologically advanced healthcare infrastructure and innovations that lead to intense competition among market players in this region.
What is Global Leukocytoclastic Vasculitis Market Scenario in the Asia Pacific Region?
Asia pacific is the rapidly growing market due to growing geriatric population suffering from a chronic disease associated leukocytoclastic vasculitis, increased funding by pharmaceutical companies in the R and D Sector and rising public health awareness resulting in early diagnosis and treatment. Emerging countries such as China and India having large population base offers huge market opportunities. Growing geriatric population suffering from leukocytoclastic vasculitis in India and China, favorable government initiatives to accelerate the R and D activities related to develop new drugs for leukocytoclastic vasculitis treatment and increasing disposable income making it affordable for peoples in this region.
What is the Repercussion of the Pandemic on the Growth of the Global Leukocytoclastic Vasculitis Market?
The COVID-19 pandemic has brought on challenges to acute care patients as well as on chronic care of patients. Patients taking immunosuppressant are more susceptible to COVID-19 infection. Due to the coronavirus outbreak supply chain of leukocytoclastic vasculitis treatment is disturbed. COVID-19 outbreak in December 2019, had affected the global economy that halted the operations of various enterprises and manufacturing facilities. The business across the globe has experienced a lack of raw material, labour shortage, a break on transportation which projected the modification in the Global leukocytoclastic vasculitis market growth in the forecast period.
However, manufacturers might not be able to purchase the ingredients like before. There are notable supply chain challenges for the Global leukocytoclastic vasculitis market, but concerns related to health and environment during the pandemic are expected to have minimal impact on the growth of the Global leukocytoclastic vasculitis market in the short term.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, ingredients, forms, patient type and distribution channels.
The report on Global leukocytoclastic vasculitis market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2016 – 2020
- Market Size & Forecast 2021 to 2031
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
- Market Drivers and Restraints
Regional analysis for Global leukocytoclastic vasculitis market includes
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
